Clinical effect of bevacizumab combined with paclitaxel and carboplatin chemotherapy regimen in patientswith advanced ovarian cancer
贝伐珠单抗联合紫杉醇与卡铂化疗方案治疗晚期卵巢癌患者的临床效果

摘要

目的 探讨贝伐珠单抗联合紫杉醇与卡铂化疗方案治疗晚期卵巢癌患者的临床疗效。方法 选择2020-2021年收治在我院的96例晚期卵巢癌病人，分为研究组、对照组，每组48例。对照组患者采用紫杉醇+卡铂联合化疗方案，研究组患者采用贝伐珠单抗联合紫杉醇与卡铂化疗方案，连续化疗6个月。对两组患者的临床效果、治疗前后的血清学和副反应进行对比分析。结果 研究组患者的总有效率68.75%高于对照组的43.75%，（2=6.095，P=0.0014）。两组病人的血药指数都明显降低，且研究组低于对照组（P＜0．05）。研究组中三级及以上的副作用发生率为18.75%（9/48）；对照组中三级及以上的副作用发生率为14.58%（7/48），两者间无显著性差异（P>0.05）。结论 贝伐珠单抗联合紫杉醇、卡铂化疗对晚期卵巢肿瘤的治疗效果明显，能明显改善患者的血清学指标和生活质量，且副作用不明显，患者的生活质量得到了改善，可以推广运用。

Abstract

Objective To investigate the clinical efficacy of bevacizumab combined with paclitaxel and carboplatin as a chemotherapy regimen in patients with advanced ovarian cancer.
Methods The 96 advanced ovarian cancer patients admitted to our hospital from 2020 to 2021 were divided into research group and control group, with 48 patients in each group. The control group of patients used paclitaxel plus carboplatin combined chemotherapy regimen, and the study group of patients used bevacizumab plus paclitaxel and carboplatin combined chemotherapy regimen for 6 months. The clinical effects of patients, serology and side reactions before and after treatment were compared in both groups.
Results The total response rate of the patients in the study group was 68.75% higher than the 43.75% in the control group, (2=6.095, P=0.0014). Blood drug index was significantly lower in both groups, and the study group was lower than the control group (P <0.05). The incidence of side effects of grade III and above in the study group was 18.75% (9 / 48), and 14.58% (7 / 48) in the control group, with no significant difference (P> 0.05).
Conclusion   Bevacizumab combined with paclitaxel and carboplatin chemotherapy has an obvious therapeutic effect on advanced ovarian tumors, which can significantly improve the serological index and quality of life of patients, and the side effects are not obvious, and the quality of life of patients has been improved, which can be popularized.